This post was originally published on this site.
The Trump administration has opened the door for Nvidia to sell its advanced AI chips in China.
The US Department of Commerce said on Tuesday that the Bureau of Industry and Security is revising its license review policy for exports of certain semiconductors to China and Macau – “changing it from a presumption of denial to a case-by-case review”.
Read more: Stocks rise as China trade surplus hits record high
Nvidia’s (NVDA) H200 AI chips come under this rule, as well as its less advanced semiconductors.
The chipmaking giant’s share price was little changed in pre-market trading on Wednesday. Nvidia (NVDA) had not responded to Yahoo Finance UK’s request for comment at the time of writing.
Fellow chipmaker Intel (INTC) was also in the spotlight on Wednesday, with shares up 3.7% in pre-market trading, after jumping 7.3% in the previous session.
Shares rose after investment firm KeyBanc upgraded its rating on the stock to “overweight”, highlighting Intel’s (INTC) advances in its manufacturing business and demand for its chips from AI data centres.
Read more: Gold price climbs to record high on Fed interest rate cut bets
Analyst John Vinh said in a note on Tuesday that Big Tech’s demand for chips and servers to power AI is leading to higher sales of Intel’s central processing units (CPUs).
Vinh said his supply chain checks show Intel (INTC) is “almost sold out for the year” in data center server CPUs and may raise prices on the chips.
Biotechnology company Moderna (MRNA) is trending, after shares surged 17% in Tuesday’s session.
The jump in shares came after Moderna (MRNA) provided an upbeat update on its guidance for the year on Tuesday.
Moderna (MRNA) said it expected 2025 revenue to come in at approximately $1.9bn (£1.4bn), which would be $100m higher than the midpoint offered in its third quarter earnings call.
Read more: Stocks that are trending today
Stéphane Bancel, CEO of Moderna (MRNA), said: “We remain focused on our strategy to build a large seasonal vaccine franchise for at-risk populations, creating a strong cash engine to fund our next phase of innovation in oncology and rare disease.”
“We expect this approach to support up to 10% revenue growth in 2026, as we further reduce costs, expand our commercial portfolio with approvals of additional seasonal vaccines, and anticipate multiple clinical data catalysts driven by our late-stage oncology pipeline.”
In the UK, BP (BP.L) was one of the biggest fallers on the FTSE 100 (^FTSE) on Wednesday morning, with shares down 1.6% at the time of writing.
BP (BP.L) warned in a fourth-quarter trading statement that its full results for the period, due out on 10 February, are expected to include up to $5bn in writedowns, primarily related to its transition businesses.
Stocks: Create your watchlist and portfolio
Maurizio Carulli, global energy and materials analyst at Quilter Cheviot, said: “BP’s investment case is unaffected by the impairments announced today and instead rests on the refocusing of the business towards the core hydrocarbon activities.”
“These were initiated by the recently departed CEO, Murray Auchincloss, and are set to accelerate under the new chairman and incoming CEO who will start in April.”
On the FTSE 250 (^FTMC), shares in Vistry (VTY.L) slid 8.5% on Wednesday morning, after the housebuilder’s full-year trading update failed to impress investors.
Vistry (VTY.L) said group adjusted pre-tax profit was expected to be around £270m ($363m) for the year, which would be up from £263.5m for the 2024 financial year and would be in line with expectations.
The company said that revenue of £4.2bn was broadly flat, though total completions of around 15,700 units were down 9% from the previous year.
Read more: Stocks to watch in 2026
Aarin Chiekrie, equity analyst at Hargreaves Lansdown, said: “It was hard for Vistry (VTY.L) to disappoint markets more than it did in 2024, when it issued three profit warnings in as many months. Vistry’s 2025 full-year results weren’t the finished product, but investors will take slight comfort knowing it was a step in the right direction.”
“While Vistry (VTY.L) is better-positioned than most to benefit from the government’s pledge to invest an unprecedented £39bn in affordable housing over the next decade, it’s likely to be a slow-burning opportunity rather than a quick win,” he said.
Read more:
Download the Yahoo Finance app, available for Apple and Android.